Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Baricitinib treatment of severe chronic hand eczema: Two case reports
Fieke M. Rosenberg, Laura Loman, Marie L. A. Schuttelaar
Contact Dermatitis (2022) Vol. 86, Iss. 5, pp. 419-421
Open Access | Times Cited: 24

Showing 24 citing articles:

JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review
Aishwarya Muddebihal, Ananta Khurana, Kabir Sardana
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 4, pp. 279-295
Closed Access | Times Cited: 18
Chronic Hand Eczema
Elke Weißhaar
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 6, pp. 909-926
Open Access | Times Cited: 7
A Review of Existing and New Treatments for the Management of Hand Eczema
Jessica S. S. Ho, Sonja Molin
Journal of Cutaneous Medicine and Surgery (2023) Vol. 27, Iss. 5, pp. 493-503
Open Access | Times Cited: 14
Real-world Experience of Abrocitinib on Difficult-to-treat Hand Eczema in Chinese Patients
Yiting Li, X. Gary Tan, Shu Nie, et al.
Acta Dermato Venereologica (2024) Vol. 104, pp. adv39822-adv39822
Open Access | Times Cited: 5
Nine cases of chronic hand and foot eczema treated with baricitinib
Sang‐Doo Lee, Hye‐Jin Ahn, Min Kyung Shin
Australasian Journal of Dermatology (2023) Vol. 64, Iss. 3, pp. 408-412
Closed Access | Times Cited: 11
A Review of Hand Eczema Subtypes: Clinical Features, Biomarkers and Treatment Strategies
David Pesqué, J.F. Silvestre, Carolina Figueiredo, et al.
Contact Dermatitis (2025)
Closed Access
Chronic Hand Eczema (CHE): A Narrative Review
G. Ghezzi, Costanza Falcidia, Giovanni Paolino, et al.
Dermatology and Therapy (2025)
Open Access
Presente y futuro del tratamiento biológico y moléculas pequeñas en el eccema crónico de manos
F.J. Navarro‐Triviño, J.P. Velasco-Amador
Piel (2025)
Closed Access
Manage chronic hand eczema with conventional treatments, but emerging therapies show promise
Amy Zhuang-Yan
Drugs & Therapy Perspectives (2025)
Closed Access
Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders
L. Corbella‐Bagot, Constanza Riquelme‐Mc Loughlin, D. Morgado-Carrasco
Actas Dermo-Sifiliográficas (2023) Vol. 114, Iss. 9, pp. 784-801
Open Access | Times Cited: 10
Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema: A Retrospective Study
Claudia Paganini, Virginia Maffei, Laura Vellucci, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 7, pp. 1876-1876
Open Access | Times Cited: 3
New Perspectives in the Management of Chronic Hand Eczema: Lessons from Pathogenesis
Vittorio Tancredi, Dario Buononato, Stefano Caccavale, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 362-362
Open Access | Times Cited: 7
Transcriptomics- and Genomics-Guided Drug Repurposing for the Treatment of Vesicular Hand Eczema
Fieke M. Rosenberg, Zoha Kamali, Angelique N. Voorberg, et al.
Pharmaceutics (2024) Vol. 16, Iss. 4, pp. 476-476
Open Access | Times Cited: 2
Topical and systemic JAK inhibitors in hand eczema – a narrative review
Adam Zalewski, Jacek C. Szepietowski
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 4, pp. 365-373
Closed Access | Times Cited: 6
A Case of Paradoxical Reactions to Biologic Therapy for Psoriasis
Qianqian Zhou, Shengru Zhou, Huizi Xiong, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 1493-1497
Open Access | Times Cited: 5
Successful Treatment of Atopic Hand and Foot Eczema With Oral Janus Kinase 1 Inhibition
Sebastian Sitaru, Sarah Preis, Bernadette Eberlein
Dermatitis (2023) Vol. 34, Iss. 6, pp. 560-560
Closed Access | Times Cited: 4
[Artículo traducido] Perfil de seguridad a largo plazo y usos fuera de indicación de los inhibidores de JAK en dermatología
L. Corbella‐Bagot, Constanza Riquelme‐Mc Loughlin, D. Morgado-Carrasco
Actas Dermo-Sifiliográficas (2023) Vol. 114, Iss. 9, pp. T784-T801
Open Access | Times Cited: 4
Topical ruxolitinib 1.5% (JAK1/JAK2 inhibitor) improves clinical and patient‐reported outcomes in moderate to severe chronic hand dermatitis: Data from a small open‐label trial
Hannah Smith, J. Lally, Alison Moy, et al.
JEADV Clinical Practice (2024) Vol. 3, Iss. 4, pp. 1016-1026
Open Access | Times Cited: 1
Immunological Advancements In Hand Eczema Treatment: Progress With Small Molecules and Biologics
Katerina Grafanaki, Alexandros Maniatis, Charalabos Antonatos, et al.
Current Treatment Options in Allergy (2024)
Closed Access | Times Cited: 1
Eczematous Disorders
Avad Mughal, J.R. Ingram
(2024), pp. 1-41
Closed Access
Challenges in the Diagnosis and Treatment of Dermatitis Related to the Elderly
Yue Hu
Advances in medical diagnosis, treatment, and care (AMDTC) book series (2024), pp. 236-254
Closed Access
Th1 and Th2 cytokine expression in hyperkeratotic chronic hand eczema and the role of Tofacitinib a oral JAK inhibitor
Kabir Sardana, Savitha Sharath, Ananta Khurana, et al.
Archives of Dermatological Research (2024) Vol. 316, Iss. 10
Closed Access
Behandlung nach Stufenschema
Peter Elsner, Sibylle Schliemann
Deleted Journal (2023) Vol. 71, Iss. 1, pp. 44-55
Closed Access
Page 1

Scroll to top